A view of Lilly corporate headquarters in Downtown Indianapolis with I-70 in the foreground. / Joe Vitti / The Star file photo

Written by

For the second time in a late-stage trial, Eli Lilly and Co. reported success in treating stomach cancer in patients with its experimental cancer drug ramucirumab. But the drug failed to hit goals in a separate study to treat breast cancer.

The mixed news on the drug played poorly on Wall Street on Thursday. Lilly stock traded down 3 percent, or $1.57 a share, to $51.04 on the New York Exchange.

The latest positive results for ramucirumab in stomach cancer seemed significant because they came in a large 665-patient Phase 3 trial that began in 2010 in 27 countries, Lilly said. ...